PROVECTUS BIOPHARMACEUTICALS, INC.
PVCT evidence brief
What we can confirm
- BioSniper Score:
- 5.5 / 10
- Market Cap:
- $24.0M
- Lead Asset:
- ph-10
What it means
What to watch
Prepared research question
What matters most for PVCT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PVCT
Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing intratumoral PV-10 and systemic RBS for oncology, with a cash position of $1.2M as of 2026-06-30 and significant going-concern risk.
Key risk: Cash runway and going concern
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$24.0M
Cash Runway
—
Lead Asset
ph-10
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 1 clinical trial for PROVECTUS BIOPHARMACEUTICALS, INC..
Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing intratumoral PV-10 and systemic RBS for oncology, with a cash position of $1.2M as of 2026-06-30 and significant going-concern risk.
- Cash & equivalents of $1.2M as of 2026-06-30 [sec].
- Net income of -$1.0M as of 2026-06-30 [sec].
- Shareholders' equity of -$6.3M as of 2026-06-30 [sec].
- Company is conducting clinical trials in melanoma and liver cancer with intratumoral PV-10 [sec_mda · as of 2026-08-13].
- Developing a systemically administered formulation of pharmaceutical-grade RBS for cancer treatment [sec_mda · as of 2026-08-13].
What works
- Company has ongoing clinical trials in melanoma and liver cancer, generating clinical data for potential drug approval pathways [sec_mda · as of 2026-08-13].
- Developing a systemic RBS formulation, which could expand its pipeline beyond intratumoral therapies [sec_mda · as of 2026-08-13].
- Management is actively pursuing co-development relationships with commercial pharmaceutical companies [sec_mda · as of 2026-08-13].
What to weigh
- Cash & equivalents of only $1.2M as of 2026-06-30, with negative shareholders' equity of -$6.3M [sec].
- Significant funds will be needed to continue and complete ongoing and planned clinical trials, with no assurance of successful financing [sec_mda · as of 2026-08-13].
- Company has an accumulated deficit and relies on future financings, including convertible notes, to meet cash requirements [sec_mda · as of 2026-08-13].
- 2025 Convertible Notes automatically convert to preferred stock at maturity, but repayment risk exists upon change of control or default [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Ongoing clinical trials in melanoma and liver cancer
“-10 clinical trials in melanoma and liver cancer indications to generate more and/or new clinical data”
SEC MD&A · August 13, 2026
Risks & what to watch (4)›
Key risks
- Cash runway and going concern — Cash of $1.2M as of 2026-06-30 is insufficient to fund operations; management plans to raise capital but no assurance of success [sec].
- Negative shareholders' equity — Shareholders' equity of -$6.3M as of 2026-06-30 indicates accumulated deficits exceeding assets [sec].
- Convertible note repayment risk — $3.3M in 2025 Convertible Notes automatically convert to preferred stock at maturity but are repayable upon change of control or default [sec_mda · as of 2026-08-13].
- Clinical trial funding dependency — Significant funds needed to continue and complete ongoing and planned clinical trials; failure to raise capital could halt development [sec_mda · as of 2026-08-13].
What to watch
- Ability to raise additional capital through equity or debt financings [sec_mda · as of 2026-08-13].
- Progress and data from ongoing PV-10 clinical trials in melanoma and liver cancer [sec_mda · as of 2026-08-13].
- Filing of an IND for systemic RBS formulation and initiation of early-stage clinical trial [sec_mda · as of 2026-08-13].
- Potential co-development partnerships with commercial pharmaceutical companies [sec_mda · as of 2026-08-13].
Sources: SEC MD&A · Generated September 24, 2026 · How we verify sources →
Run PROVECTUS BIOPHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PROVECTUS BIOPHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$983K
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 0.8%
- Days to cover
- 0.5
- Shares short
- 1,821,793
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PVCT short interestGovernance
Frequently asked questions
What is the AI investment thesis for PROVECTUS BIOPHARMACEUTICALS, INC.?
Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing intratumoral PV-10 and systemic RBS for oncology, with a cash position of $1.2M as of 2026-06-30 and significant going-concern risk.
Who is the CEO of PROVECTUS BIOPHARMACEUTICALS, INC.?
Mr. Edward V. Pershing CPA is the chief executive officer of PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT).
Where is PROVECTUS BIOPHARMACEUTICALS, INC. headquartered?
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) is headquartered in Knoxville, TN, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.